Abstract
Tumor necrosis factor (TNF) plays an important role in the pathogenesis of breast cancer (BC). The -308(G/A)TNF polymorphism allele -308A is part of the autoimmune ancestral haplotype AH8.1 associated with elevated serum sTNF levels. Previously, we showed a decrease in overall survival for carriers -308A/AH8.1-. The aim of the study was to assess the effect of haplotypes AH8.1 on the level of sTNF and clinical and morphological characteristics of BC patients. The study included 100 people with adjuvant radiotherapy treatment. The concentration of sTNF was determined by the ELISA. Additionally, 30 archival DNA samples of primary BC patients carrying the allele -308A with a known sTNF level were genotyped. Alleles -308(G/A)TNF and marker alleles of haplotype AH8.1 (HLA-A*01, HLA-B*08 and HLA-DRB1*03) were determined by allele-specific PCR. Based on the polymorphism of -308(G/A)TNF and marker alleles of haplotype AH8.1, three comparison groups were identified: -308GG carriers of the TNF gene independently of haplotype AH8.1 (76%), which were used as a control; -308A/AH8.1- carriers (9%); and -308A/M(AH8.1)+ carriers of at least one haplotype AH8.1 allele (15%). The comparison groups had no statistically significant differences regarding the stage of the disease, the degree of malignancy, the histological type, and the receptor status of the tumor. The level of sTNF was significantly higher in the genetic group -308A/AH8.1– both before surgery and before and after adjuvant radiotherapy. In BC patient carriers of the TNF gene allele -308A, the autoimmune haplotype AH8.1 has a normalizing effect on the production of sTNF to a level comparable to the level of cytokine in the group of carriers of the common -308GG genotype. The genetic group -308A/AH8.1– with an increased level of sTNF has been identified, for which, bearing in mind its prognostic unfavorability, anti-TNF therapy can presumably be offered. The results obtained can be used in the framework of personalized medicine.
REFERENCES
Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2021 gody (The State of Oncological Care to the Population of Russia in 2021), Kaprin, A.D., Starinskii, V.V., and Shakhzadova, A.O., Eds., Moscow: P.A. Herzen Moscow State Medical Research Institute - Branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of Russia, 2022, p. 239. https://oncology-association.ru.
Waters, J.P., Pober, J.S., and Bradley, J.R., Tumor necrosis factor and cancer, J. Pathol., 2013, vol. 230, no. 3, pp. 241–248. https://doi.org/10.1002/path.4188
Herrera, A.C.S.A., Panis, C., Victorino, V.J., Campos, F.C., Colado-Simão, A.N., Cecchini, A.L., and Cecchini, R., Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients, Cancer Immunol. Immunother., 2012, vol. 61, no. 11, pp. 2193–2201. https://doi.org/10.1007/s00262-012-1283-8
Ma, Y., Ren, Y., Dai, Z.-J., Wu, C.-J., Ji, Y.-H., and Xu, J., IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients, Adv. Clin. Exp. Med., 2017, vol. 26, no. 3, pp. 421–426. https://doi.org/10.17219/acem/62120
Autenshlyus, A.I., Studenikina, A.A., Varaksin, N.A., and Lyakhovich, V.V., Cytokine production by tumor bioptate at different pathological prognostic stages in breast cancer, Dokl. Biochem. Biophys., 2021, vol. 497, no. 1, pp. 86–89. https://doi.org/10.1134/S1607672921020010
Aly, T.A., Eller, E., Ide, A., Gowan, K., Babu, S.R., Erlich, H.A., et al., Multi-SNP analysis of MHC region: remarkable conservation of HLA-A1-B8-DR3 haplotype, Diabetes, 2006, vol. 55, no. 5, pp. 1265–1269. https://doi.org/10.2337/db05-1276
Dawkins, R.L. and Lloyd, S.S., MHC genomics and disease: looking back to go forward, Cells, 2019, vol. 8, no. 9, p. 944. https://doi.org/10.3390/cells8090944
Wilson, A.G., Symons, J.A., McDowell, T.L., McDevitt, H.O., and Duff, G.W., Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation, Proc. Natl. Acad. Sci. U. S. A., 1997, vol. 94, no. 7, pp. 3195–3199. https://doi.org/10.1073/pnas.94.7.3195
Malivanova, T.F., Alferova, E.V., Ostashkin, A.S., Astrelina, T.A., and Mazurenko, N.N., The overall survival of breast cancer patients depends on a combination of polymorphisms of tumor necrosis factor gene and HLA haplotypes, Mol. Genet., Microbiol. Virol., 2020, vol. 35, pp. 38–46. https://doi.org/10.3103/S0891416817030053
Malivanova, T.F., Ostashkin, A.S., and Mazurenko, N.N., The connection of polymorphisms–238A/G TNF and Ile655Val HER2 influences the risk and molecular features of breast cancer, Mol. Genet., Microbiol. Virol., 2017, vol. 32, pp. 141–147. https://doi.org/10.3103/S0891416817030053
Mercogliano, M.F., Bruni, S., Elizalde, P.V. and Schillaci, R., Tumor necrosis factor α blockade: an opportunity to tackle breast cancer, Front. Oncol., 2020, vol. 10, p. 584. https://doi.org/10.3389/fonc.2020.00584
Ben-Baruch, A., Tumor necrosis factor a: taking a personalized road in cancer therapy, Front. Immunol., 2022, vol. 13, p. 903679. https://doi.org/10.3389/fimmu.2022.903679
Thriveni, K., Raju, A., Ramaswamy, G., and Krishnamurthy, S., Impact of gene polymorphism of TNF-α rs 1800629 and TNF-β rs 909253 on plasma levels of South Indian breast cancer patients, Indian J. Cancer, 2018, vol. 55, no. 2, pp. 179–183. https://doi.org/10.4103/ijc.IJC_591_17
Bounder, G., Jouimyi, M.R., Boura, H., Touati, E., Michel, V., Badre, W., et al., Associations of the -238(G/A) and -308(G/A) TNF-α promoter polymorphisms and TNF-α serum levels with the susceptibility to gastric precancerous lesions and gastric cancer related to Helicobacter pylori infection in a Moroccan population, Asian Pac. J. Cancer Prev., 2020, vol. 21, no. 6, pp. 1623–1629. https://doi.org/10.31557/APJCP.2020.21.6.1623
Mahto, H., Tripathy, R., Meher, B.R., Prusty, B.K., Sharma, M., Deogharia, D., et al., TNF-α promoter polymorphisms (G-238A and G-308A) are associated with susceptibility to Systemic Lupus Erythematosus (SLE) and P. falciparum malaria: a study in malaria endemic area, Sci. Rep., 2019, vol. 9, no. 1, p. 11752. https://doi.org/10.1038/s41598-019-48182-5
Abraham, L.J., French, M.A., and Dawkins, R.L., Polymorphic MHC ancestral haplotypes affect the activity of tumor necrosis factor-alpha, Clin. Exp. Immunol., 1993, vol. 92, no. 1, pp. 14–18. https://doi.org/10.1111/j.1365-2249.1993.tb05940.x
Pooja, S., Francis, A., Bid, H.K., Kumar, S., Rajender, S., Ramalingam, K., et al., Role of ethnic variations in TNF-α and TNF-β polymorphisms and risk of breast cancer in India, Breast Cancer Res. Treat., 2011, vol. 126, no. 3, pp. 739–747. https://doi.org/10.1007/s10549-010-1175-6
Wang, Z., Kong, L., Zhang, H., Sun, F., Guo, Z., Zhang, R., and Dou, Y., Tumor necrosis factor alpha ‑308G/A gene polymorphisms combined with neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio predicts the efficacy and safety of anti-TNF-α therapy in patients with ankylosing spondylitis, rheumatoid arthritis, and psoriasis arthritis, Front. Pharmacol., 2022, vol. 12, p. 811719. https://doi.org/10.3389/fphar.2021.811719
Kaur, G., Kumar, N., Szilagyi, A., Blasko, B., Fust, G., Rajczy, K., et al., Autoimmune-associated HLA-B8-DR3 haplotypes in Asian Indians are unique in C4 complement gene copy numbers and HSP-2 1267A/G, Hum. Immunol., 2008, vol. 69, no. 9, pp. 580–587. https://doi.org/10.1016/j.humimm.2008.06.007
Valente, F.P., Tan, C., Phipps, M., Witt, C.S., Kaur, G., Gut, I., et al., TNF block haplotypes associated with conserved MHC haplotypes in European, Asian and Australian aboriginal donors, Tissue Antigens, 2009, vol. 74, no. 1, pp. 57–61. https://doi.org/10.1111/j.1399-0039.2009.01258.x
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflicts of interest.
Statement of Compliance with Standards of Research involving Humans as Subjects
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants involved in the study.
Additional information
Translated by A. Kazantseva
About this article
Cite this article
Malivanova, T.F., Astrelina, T.A., Kobzeva, I.V. et al. Autoimmune Haplotype AH8.1 Normalizes the Level of Tumor Necrosis Factor in the Blood Sera of Breast-Cancer Patients. Mol. Genet. Microbiol. Virol. 38, 34–40 (2023). https://doi.org/10.3103/S089141682301007X
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3103/S089141682301007X